Home / Market News / $JNJ
benzinga Corporate Catalyst Impact 75/100 ● positive

Johnson & Johnson Clinical Trials Show Progress Across Key Therapies

Sep 25, 2026, 3:03 PM UTC · Primary ticker $JNJ

Johnson & Johnson announced positive clinical trial results for two key therapies: Tremfya for psoriatic arthritis and Carvykti for multiple myeloma. These findings indicate strong efficacy and safety profiles, potentially bolstering J&J's pharmaceutical pipeline and market position in these therapeutic areas.

Johnson & Johnson reported positive clinical trial data for Tremfya in psoriatic arthritis and Carvykti in multiple myeloma. Tremfya met primary and secondary endpoints in a Phase 4 study, showing significant improvement in axial symptoms and reduced inflammation, while Carvykti demonstrated five-year progression-free remissions in a Phase 2 study. This news is a significant positive for J&J, as it validates the efficacy and safety of two important drugs in their portfolio, potentially leading to increased market share and revenue in the long term. For traders, this reinforces J&J's strong pharmaceutical pipeline, offering a positive outlook, though the immediate stock reaction was slightly down, suggesting the market may have already priced in some of this success or is reacting to broader market trends.

$JNJ positive Positive clinical trial results for key drugs
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.